158 related articles for article (PubMed ID: 31446456)
1. Addictive response of primary cutaneous diffuse large B cell lymphoma leg type to low-dose ibrutinib.
Pang A; Au-Yeung R; Leung RYY; Kwong YL
Ann Hematol; 2019 Oct; 98(10):2433-2436. PubMed ID: 31446456
[No Abstract] [Full Text] [Related]
2. Intravascular large B cell lymphoma: widespread but not everywhere.
Ponzoni M; Ferreri AJ
Acta Haematol; 2014; 131(1):16-7. PubMed ID: 24021531
[No Abstract] [Full Text] [Related]
3. What is your diagnosis? Cutaneous B-cell lymphoma.
Carlson SW; Aneja S; Honda K; Cooper KD
Cutis; 2014 Nov; 94(5):217, quiz 249-51. PubMed ID: 25474456
[No Abstract] [Full Text] [Related]
4. Promising new combination therapy for non-GCB DLBCL.
Gourd E
Lancet Oncol; 2019 May; 20(5):e245. PubMed ID: 30930026
[No Abstract] [Full Text] [Related]
5. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
Younes A; Sehn LH; Johnson P; Zinzani PL; Hong X; Zhu J; Patti C; Belada D; Samoilova O; Suh C; Leppä S; Rai S; Turgut M; Jurczak W; Cheung MC; Gurion R; Yeh SP; Lopez-Hernandez A; Dührsen U; Thieblemont C; Chiattone CS; Balasubramanian S; Carey J; Liu G; Shreeve SM; Sun S; Zhuang SH; Vermeulen J; Staudt LM; Wilson W;
J Clin Oncol; 2019 May; 37(15):1285-1295. PubMed ID: 30901302
[TBL] [Abstract][Full Text] [Related]
6. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
Fabbri A; Gozzetti A; Rigacci L
Cancer; 2011 Aug; 117(15):3530; author reply 3531. PubMed ID: 21287541
[No Abstract] [Full Text] [Related]
7. A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis.
Yoon SE; Kim SJ; Yoon DH; Koh Y; Mun YC; Do YR; Choi YS; Yang DH; Kim MK; Lee GW; Suh C; Ko YH; Kim WS
Ann Hematol; 2020 Jun; 99(6):1283-1291. PubMed ID: 32333154
[TBL] [Abstract][Full Text] [Related]
8. Autoimmune myelitis in a CLL patient undergoing treatment with ibrutinib.
Wanner D; Bohn JP; Rudzki J; Stockhammer G; Steurer M
Ann Hematol; 2019 Jan; 98(1):205-207. PubMed ID: 29804266
[No Abstract] [Full Text] [Related]
9. Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab.
Grange F; Maubec E; Bagot M; Beylot-Barry M; Joly P; Dalle S; Delaporte E; Dereure O; Bachelez H; Vergier B; Petrella T; D'Incan M
Arch Dermatol; 2009 Mar; 145(3):329-30. PubMed ID: 19289772
[No Abstract] [Full Text] [Related]
10. Two independent consecutive lymphoma cases carry an identical MYD88 mutation but differ in their IGVH rearrangement.
Prieto-Torres L; Trascasa Á; Manso R; Machan S; Cieza-Diaz D; Olmedilla G; García-García M; Ara-Martín M; Requena L; Piris MÁ; Rodríguez-Pinilla SM
Br J Haematol; 2020 Sep; 190(6):e352-e356. PubMed ID: 32578872
[No Abstract] [Full Text] [Related]
11. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
Musolino A; Boggiani D; Panebianco M; Vasini G; Salvagni S; Franciosi V; Ardizzoni A
Cancer; 2011 Mar; 117(5):964-73. PubMed ID: 20960528
[TBL] [Abstract][Full Text] [Related]
12.
Swan CD; Gottlieb T
BMJ Case Rep; 2018 Jul; 2018():. PubMed ID: 30021735
[TBL] [Abstract][Full Text] [Related]
13. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
14. [Standard of care and new drugs for diffuse large B-cell lymphoma].
Yamamoto K
Rinsho Ketsueki; 2014 Oct; 55(10):1920-8. PubMed ID: 25297756
[No Abstract] [Full Text] [Related]
15. Secondary cutaneous Epstein-Barr virus-associated diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma: a case report and review of literature.
Yang QX; Pei XJ; Tian XY; Li Y; Li Z
Diagn Pathol; 2012 Jan; 7():7. PubMed ID: 22260632
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in heavily pretreated cutaneous B-cell lymphoma.
Zinzani PL; Stefoni V; Alinari L; Vianelli N; Baccarani M
Leuk Lymphoma; 2003 Sep; 44(9):1637-8. PubMed ID: 14565673
[No Abstract] [Full Text] [Related]
17. [An atypical presentation of primary cutaneous diffuse B-cell lymphoma, leg type].
Brouillard C; Granel-Brocard F; Montagne K; Bastien C; Barbaud A; Schmutz JL
Ann Dermatol Venereol; 2011; 138(8-9):601-4. PubMed ID: 21893235
[TBL] [Abstract][Full Text] [Related]
18. Metabolic tumour volume and response to therapy in diffuse large B-cell lymphoma.
Campiotti L; Suter MB; De Palma D; Proserpio I; Uccella S; Squizzato A
Hematol Oncol; 2019 Aug; 37(3):308-309. PubMed ID: 30933368
[No Abstract] [Full Text] [Related]
19. Diagnosis of a primary cardiac B-cell lymphoma.
Menke J; Unterberg-Buchwald C; Schaefer IM; Kertesz A
Am J Hematol; 2012 Apr; 87(4):426-7. PubMed ID: 21953722
[No Abstract] [Full Text] [Related]
20. [Chronic lymphocytic leukemia].
Aoki S
Rinsho Ketsueki; 2014 Feb; 55(2):213-22. PubMed ID: 24598189
[No Abstract] [Full Text] [Related]
[Next] [New Search]
